STOCK TITAN
  1. Home
  2. Sec-filings
  3. RVMD
  4. [Form 4] Revolution Medicines, Inc. Insider Trading Activity

Revolution Medicines (RVMD) CEO Mark Goldsmith exercises options, reports trust holdings

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Revolution Medicines President and CEO Mark A. Goldsmith, who also serves as a director, reported an option exercise and updated share holdings. On February 6, 2026, a stock option for 24,010 shares with a $0.54 exercise price was converted into the same number of common shares.

Following the transaction, Goldsmith directly held 256,479 shares of common stock, which the filing notes includes 168,763 restricted stock units570,050 shares in the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust and 67,424 shares in each of two additional revocable trusts.

Positive

  • None.

Negative

  • None.
Insider GOLDSMITH MARK A
Role See Remarks
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 24,010 $0.00 --
Exercise Common Stock 24,010 $0.54 $13K
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 144,493 shares (Direct); Common Stock — 256,479 shares (Direct); Common Stock — 570,050 shares (Indirect, Trust)
Footnotes (1)
  1. Includes 168,763 restricted stock units. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust. Held by Jonathan Goldsmith Revocable Trust. Held by Rebecca Goldsmith Revocable Trust.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GOLDSMITH MARK A
(Last) (First) (Middle)
C/O REVOLUTION MEDICINES, INC.
700 SAGINAW DRIVE
(Street)
REDWOOD CITY CA 94063
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/06/2026 M 24,010 A $0.54 256,479(1) D
Common Stock 570,050 I Trust(2)
Common Stock 67,424 I Trust(3)
Common Stock 67,424 I Trust(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $0.54 02/06/2026 M 24,010 03/01/2022 02/11/2028 Common Stock 24,010 $0 144,493 D
Explanation of Responses:
1. Includes 168,763 restricted stock units.
2. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
3. Held by Jonathan Goldsmith Revocable Trust.
4. Held by Rebecca Goldsmith Revocable Trust.
Remarks:
President and Chief Executive Officer
/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith 02/10/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did RVMD’s Mark A. Goldsmith report?

Mark A. Goldsmith reported exercising a stock option for 24,010 shares of Revolution Medicines common stock at an exercise price of $0.54 per share. The option exercise occurred on February 6, 2026, and resulted in the issuance of 24,010 common shares.

How many RVMD shares does Mark A. Goldsmith hold directly after this Form 4?

After the reported transaction, Mark A. Goldsmith directly held 256,479 shares of Revolution Medicines common stock. The filing specifies that this direct holding includes 168,763 restricted stock units, which typically convert into common shares upon vesting under specified conditions.

What derivative securities does Mark A. Goldsmith hold in RVMD after the transaction?

Following the option exercise, Goldsmith held 144,493 stock options with a $0.54 exercise price. These options are exercisable from March 1, 2022, and expire on February 11, 2028, and are reported as being held directly in his name in the filing.

What indirect RVMD share holdings are reported for Mark A. Goldsmith?

The filing reports indirect ownership through trusts, including 570,050 Revolution Medicines shares held by the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust. It also lists 67,424 shares in the Jonathan Goldsmith Revocable Trust and 67,424 shares in the Rebecca Goldsmith Revocable Trust.

What roles does Mark A. Goldsmith hold at Revolution Medicines (RVMD)?

Mark A. Goldsmith is identified as both a director and an officer of Revolution Medicines. The remarks section clarifies that he serves as President and Chief Executive Officer, indicating he holds the company’s top executive position while also sitting on its board.

What is the significance of restricted stock units in Goldsmith’s RVMD holdings?

The filing notes that Goldsmith’s 256,479 directly held shares include 168,763 restricted stock units. Restricted stock units typically represent a promise to deliver shares in the future, usually subject to vesting conditions tied to continued service or performance.